**Abstract**

**Objective**: There is evidence that tardive dyskinesia (TD) is associated with greater cognitive impairment. Patients with schizophrenia (SCZ) with TD (SCZ-TD^+^) was reported to improve less than SCZ without TD (SCZ-TD¯) on some cognitive tests during treatment with antipsychotic drugs (APDs) other than clozapine (Caroff et al., J Clin Psychiatry, 2011). Clozapine improves some cognitive functions, especially, verbal fluency (VF). It improves working memory (WM) in the subset of patients who have higher N-desmethylclozapine (NDMC)/clozapine plasma ratio (Meltzer, Am J Psychiatry, 2015). However, overall, it worsens WM (Hagger et al., Biol Psychiatry, 1993). We have, now, examined the impact of TD on cognition after 6 wks of clozapine treatment, with special attention to WM and VF, along with assessments of the impact of clozapine and NDMC levels, and their ratio on cognition in a subsample.

**Methods**: One hundred seventeen patients (24 SCZ-TD^+^) were administrated a comprehensive cognitive, as well as psychopathology, assessments, at baseline and after 6 wks of clozapine treatment. Drug concentrations were measured in a subsample at 6 wk.

**Results**: At baseline, SCZ-TD^+^ showed significantly lower scores on the Controlled Word Association Test (CWAT), a phonemic VF test, compared to SCZ-TD¯ (p=0.003). No other cognitive test differed significantly between groups. At 6 wk, clozapine significantly improved CWAT (p\<0.02) and worsened Consonant Trigram Test (CTT) (p\<0.03), a verbal WM test, in both groups. In addition, their changes at 6 wk were negatively correlated (p\<0.03). TD^+^ was associated with significantly greater worsening of performance on the CTT (p=0.05). Plasma drug levels and their ratio were not different between groups, and was not associated with CTT or CWAT at 6 wk. TD status did not affect psychopathology at baseline or at 6 wk.

**Conclusions**: These data provide new evidence that dorsal striatal deficits, which underlie TD, may be related to cognitive impairment mediated via frontostriatal network in SCZ-TD^+^. They reinforce the need for less use of typical APDs, which has an increased risk for TD, and the need to take TD status into account in assessing cognition in SCZ and related disorders.
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